C. Blajman

3.3k total citations · 1 hit paper
15 papers, 759 citations indexed

About

C. Blajman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, C. Blajman has authored 15 papers receiving a total of 759 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in C. Blajman's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (3 papers). C. Blajman is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (3 papers). C. Blajman collaborates with scholars based in Argentina, United States and Brazil. C. Blajman's co-authors include Eric Winquist, Peter Langmuir, Vera Hirsh, Lisa Licitra, Krzysztof Składowski, Ірина Давиденко, Sandrine Faivre, Yuh‐Min Chen, Laura Emerson and Jin Soo Lee and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

C. Blajman

15 papers receiving 745 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

2013 314 citations Jan B. Vermorken, Ірина Давиденко et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by C. Blajman

Since Specialization

Citations

This map shows the geographic impact of C. Blajman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Blajman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Blajman more than expected).

Fields of papers citing papers by C. Blajman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Blajman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Blajman. The network helps show where C. Blajman may publish in the future.

Co-authorship network of co-authors of C. Blajman

This figure shows the co-authorship network connecting the top 25 collaborators of C. Blajman. A scholar is included among the top collaborators of C. Blajman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Blajman. C. Blajman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study) 2015 ·Clinical Breast Cancer ·Henry Gómez, Silvia P. Neciosup, C. Tosello, Max S. Mano, José Bines, (unknown), Patrícia Xavier Santi, Hélio Pinczowski, (unknown), Marcello Ferretti Fanelli, Luis Fein, (unknown), Guillermo Lerzo, (unknown), Juan José Zarbá, C. Blajman, Mirta Varela, Jeovany Martínez-Mesa, Gustavo Werutsky, Carlos H. Barrios	19
2	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial breakdown → 2013 ·The Lancet Oncology ·Jan B. Vermorken, (unknown), Ірина Давиденко, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Krzysztof Składowski, Makoto Tahara, Vasant R. Pai, Sandrine Faivre, C. Blajman, Arlene A. Forastiere, B. Stein, Kelly S. Oliner, Zhiying Pan, Bruce Allen Bach	314
3	Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801) 2013 ·Cancer Research ·Henry Gómez, Silvia P. Neciosup, C. Tosello, Max S. Mano, José Bines, (unknown), (unknown), (unknown), (unknown), Marcello Ferretti Fanelli, (unknown), (unknown), Guillermo Lerzo, (unknown), J. J. Zarba, C. Blajman, (unknown), Jeovany Martínez-Mesa, Gustavo Werutsky, (unknown)	2
4	Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) 2012 ·Journal of Clinical Oncology ·Jin Soo Lee, Vera Hirsh, Keunchil Park, Shukui Qin, C. Blajman, Reury-Perng Perng, Yuh‐Min Chen, Laura Emerson, Peter Langmuir, Christian Manegold	179
5	Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). 2010 ·Journal of Clinical Oncology ·(unknown), Vera Hirsh, (unknown), Shukui Qin, C. Blajman, R.-P. Perng, Lyska L. Emerson, Peter Langmuir, C. Manegold	47
6	Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation 2009 ·Annals of Oncology ·Marshall R. Posner, Charles M. Norris, Lori J. Wirth, Dong M. Shin, Kevin J. Cullen, Eric Winquist, C. Blajman, E. Mickiewicz, Gary Frenette, (unknown), Roger B. Cohen, Lynn M. Steinbrenner, (unknown), Vera Gorbunova, Sergei Tjulandin, Luis E. Raez, Douglas R. Adkins, Roy B. Tishler, Martin Roessner, Robert I. Haddad	102
7	An analysis of safety in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving chemotherapy (CT) with or without panitumumab (pmab) in a phase III clinical trial (SPECTRUM) 2009 ·Journal of Clinical Oncology ·J. B. Vermorken, (unknown), Ірина Давиденко, Eric Winquist, Lisa Licitra, (unknown), Krzysztof Składowski, C. Blajman, Sandrine Faivre, Jennifer Gansert	19
8	Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer. 2008 ·Cancer Research ·(unknown), (unknown), (unknown), C. Blajman, Luis Fein, (unknown), Matías Chacón, Mark J. Cantwell, (unknown), Jennifer D. Ellis, (unknown), Jeffrey A. Stewart, (unknown)	1
9	Tolerability and incidence of infusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution 2008 ·Journal of Clinical Oncology ·Jonas C. Schupp, (unknown), Joan M. Robbins, (unknown), (unknown), (unknown), C. Blajman, (unknown), Matías Chacón, (unknown)	1
10	Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer 2007 ·Lung Cancer ·José Rodrigues Pereira, Luis Fein, Auro del Giglio, C. Blajman, Eduardo Richardet, Gilberto Schwartsmann, Mauro Orlando, Belinda J. Hall, Teena West, Maximiliano Van Kooten	9
11	A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5‐fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma 1999 ·Cancer ·C. Blajman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), F.M. Delgado	2
12	A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma 1999 ·Cancer ·C. Blajman, (unknown), Joel A. Block, (unknown), R. Chacón, Luis Fein, (unknown), Angeles A. Alvarez, (unknown), F.M. Delgado	41
13	Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85) 1997 ·British Journal of Cancer ·(unknown), R. Chacón, (unknown), C. Blajman, (unknown), Marco J. Bruno, A. Romero, (unknown), Markus Bader, Raymund Schwan, Carlo Albera, (unknown), (unknown), Jurandir Nadal, María Eugenia Ibarrarán Viniegra	1
14	Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer 1996 ·European Journal of Cancer ·Enrique Roca, Eduardo J. Pennella, (unknown), Silvia Carraro, Mario Barugel, Carmelo A. Milano, (unknown), (unknown), G. González, (unknown), (unknown), (unknown), C. Blajman, Jurandir Nadal, María Teresa Santarelli, Alfredo Navigante	19
15	Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer. 1986 ·PubMed ·(unknown), (unknown), (unknown), C. Blajman, (unknown), Alfredo Hidalgo‐Miranda, Humberto Holmer Fiori, Markus Bader, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact